COMPARE · Data as of August 21, 2026
BSX vs STVN
Verdict: Side-by-side breakdown using the Bull Rankings model. BSX scored 78.1, STVN scored 63.4 — BSX leads.
Compare another set
Different reporting periods. BSX's fundamentals are as of June 2026, but STVN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
BSX
Boston Scientific Corporation
78.1
$50.37 · $73.0B
fundamentals as of
Score gap
14.7
BSX leads
STVN
Stevanato Group S.p.A.
63.4
$22.60 · $6.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthBSX+13.5%
- Strongest balance sheetSTVN0.29
- Highest qualityBSX71 / 100
- Largest discount to fair valueBSX-12%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
BSX
stronger →← stronger
STVN
71
Qualityreturns · margins · balance sheet
52
88
Growthrevenue & earnings expansion
75
76
Valuevaluation vs sector peers
76
BSX is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BSX
STVN
$3.6bB
FCF
-$36mF
+13.5%B+
Rev
+7.4%B
0.50B
D/E
0.29B
20.4xB+
P/E
—
0.75A-
PEG
0.37A
—
P/S
4.3xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BSX
STVN
12% below
Price vs fair valuelower is cheaper
—
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+12%
1-yr DCF upside
—
+14%
5-yr DCF upside
—
+16%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BSX
Why this score
- Buying back stock
STVN
Why this score
- Foreign reporter (EUR)
The companies
BSXBoston Scientific Corporation
Why now
Medical Devices · market cap $73.0b. Down 54% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.75 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $62.69 (implying +24% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 54% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
STVNStevanato Group S.p.A.
Why now
Medical Instruments & Supplies · market cap $6.2b. 19% off the 52-week high of $28.00. PEG 0.37 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $24.83 (implying +10% upside).
Moat
Higher-variance name — the moat signals on the quantitative card are modest, so the durability case rests on execution (turning current growth into durable earnings power) or an un-monetized asset (IP / network effects / first-mover position) rather than an entrenched competitive position.
Risk
Free cash flow is negative (-$36m) — capital raises or debt issuance likely required; dilution / leverage risk. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BSX and STVN diverge
On the headline score the gap is 14.7 points in favor of BSX. The widest single difference is Quality, where BSX leads by 19.1 points.
- QualityBSX 71.2 · STVN 52.1BSX +19.1
- GrowthBSX 88.4 · STVN 75.4BSX +13.0
- ValueBSX 75.8 · STVN 75.6level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.